Alexion Receives Rare Impact Award from the National Organization for Rare Disorders (NORD)

On May 17, Alexion was honored to receive a 2016 Rare Impact Award from the National Organization for Rare Disorders (NORD), and named as one of this year’s Industry Innovation Honorees. Alexion was selected for the award for its work in bringing two transformative therapies to market – Strensiq® (asfotase alfa), the first approved treatment for perinatal, infantile and juvenile-onset hypophosphatasia (HPP), and Kanuma® (sebelipase alfa), the first treatment for patients with lysosomal acid lipase deficiency (LAL-D). Both HPP and LAL-D are genetic, chronic and progressive, life-threatening ultra-rare metabolic diseases.

"People who make a positive impact on the rare disease community go above and beyond, overcoming certain obstacles, to make meaningful change in the lives of others,” said Peter L. Saltonstall, President and CEO of NORD. “It is our honor to recognize their work to help the 1 in 10 Americans—most of whom are children—living with rare diseases."

In its inaugural year, the Rare Impact Awards continues NORD’s 30-year tradition of bringing the entire rare disease community together to celebrate those who are making extraordinary contributions to help others. More than 500 people – including advocacy groups, companies focused on rare diseases, and patients - attended the event in Washington, D.C.

Agustin Melian, M.D., Senior Vice President of Medical Sciences & Development Operations at Alexion, recognized the rare disease community, which Alexion is dedicated to serving, and accepted the award on behalf of the 3,000 Alexion employees around the world who dedicate their professional lives to serving patients with rare and devastating diseases.

“Having two product approvals within months of each other is especially significant to us as a company focused on finding answers to the most difficult challenges in rare diseases, changing the world for patients by redefining innovation, and creating a legacy that is measured in the families we serve today, and the generations that follow, so that no one is left behind,” Dr. Melian said during his acceptance speech. “These new therapies allow us to take another step in reaching more patients suffering from rare and devastating disorders."